Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Among 2024's modest M&A action, cancer, immunology and neuroscience deals trickle in
In 2024, smaller deals have dominated pharma M&A, with no single deal surpassing $5 billion. Despite this, M&A remains crucial for refilling pipelines and supporting smaller biotechs. Notable deals include Vertex's $4.9 billion acquisition of Alpine Immune Sciences, Eli Lilly's $3.2 billion acquisition of Morphic, and Gilead's $4.3 billion purchase of CymaBay. Oncology and neuroscience have seen significant activity, with Novartis and AstraZeneca leading in oncology, and Bristol Myers Squibb and Lundbeck in neuroscience.
EMA approves Sanofi/Regeneron's Dupixent for young EoE patients
EMA approves Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, weighing at least 15kg, based on EoE KIDS trial results. Dupixent is the first approved treatment for these young patients, with efficacy and safety consistent with its profile in adolescents and adults.
Sanofi/Regeneron's Dupixent approved by EC for younger eosinophilic oesophagitis patients
Sanofi and Regeneron's Dupixent approved by EC for EoE in children aged 1-11 years, weighing at least 15kg, not controlled by conventional therapy. Dupixent showed 68% histological remission vs 3% placebo in phase 3 EoE KIDS trial, with sustained results up to one year.
EU approves Dupixent for treating eosinophilic esophagitis in young children
EMA approves Sanofi and Regeneron's Dupixent for treating eosinophilic esophagitis in children aged 1-11 years, marking the first EU approval for this age group. Dupixent, a monoclonal antibody targeting IL4 and IL13 pathways, showed efficacy in a phase 3 trial, with 68% of children achieving histological disease remission.
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies
DelveInsight's 'Severe Asthma Pipeline Insight 2024' highlights 40+ companies developing 50+ therapies, including promising candidates like KN-002, BAT2606, CM326, and others. Key companies include Kinaset Therapeutics, GlaxoSmithKline, Sanofi, and AstraZeneca. Recent milestones include positive phase III results for GSK's depemokimab and phase IIb data for Sanofi's rilzabrutinib. The report covers global pipeline, therapeutic assessments, and key insights on severe asthma treatment.
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Dupixent is now approved in the EU for treating eosinophilic esophagitis (EoE) in children aged 1-11, making it the first and only medicine indicated for this age group. The approval is based on the EoE KIDS phase 3 study, showing Dupixent's efficacy and safety in children similar to older EoE patients. Dupixent, an injection inhibiting IL4 and IL13 pathways, aims to improve the quality of life for young EoE patients.
EMA approves Dupixent for young EoE patients
EMA approved Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, based on EoE KIDS trial results. Dupixent is the first approved treatment for young EoE patients in EU, Canada, and US.
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
The European Medicines Agency approves Dupixent for eosinophilic esophagitis in children aged 1-11 years, making it the first treatment for this age group. The approval is based on the EoE KIDS phase 3 study showing Dupixent's efficacy and safety in children, with 68% achieving histological disease remission compared to 3% with placebo. Dupixent is administered subcutaneously and inhibits the IL4 and IL13 pathways, addressing type-2 inflammation.
Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of drug approvals
Top 20 biopharmaceutical companies saw a 2% market cap increase in Q3 2024, driven by FDA approvals and strategic alliances. Bristol Myers Squibb led with a 24.6% growth, fueled by Cobenfy's approval and a $3.5bn deal with Prime Medicine. Gilead Sciences and Sanofi also grew significantly due to new drug approvals. Despite some declines, industry recovery is expected, supported by Federal Reserve interest rate cuts.
A diabetes drug, twice rejected, stumbles again — but its developer persists
Lexicon Pharmaceuticals faces FDA rejections for sotagliflozin, its type 1 diabetes and chronic kidney disease drug, with an advisory committee voting against its approval. Despite setbacks, Lexicon continues development and anticipates an FDA decision by December 20.
© Copyright 2025. All Rights Reserved by MedPath